Determination 2
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
Arms / Cohorts
Experimental:Arm F: Cohort 2 Randomized Consolidation and Maintenance (Linvoseltamab Strategy)
Not yet accepting
Other:Arm G: Cohort 2 Non-randomized 3-Drug Maintenance
Not yet accepting
Other:Arm A: Induction and Screening
Not yet accepting
Experimental:Arm B: Cohort 1 Maintenance Therapy Part 1
Not yet accepting
Experimental:Arm C: Cohort 1 Maintenance Therapy Part 2, Single-Agent Iberdomide
Not yet accepting
Experimental:Arm D: Cohort 1 Maintenance Therapy Part 2, Iberdomide + Isatuximab
Not yet accepting
Active Comparator:Arm E: Cohort 2 Randomized Consolidation and Maintenance (HDM-ASCT Strategy)
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.